scholarly journals Gestión del cambio organizacional por covid-19 en las cooperativas de la ciudad de Pilar

2021 ◽  
Vol 5 (4) ◽  
pp. 4914-4936
Keyword(s):  
Lewis Y

La investigación tuvo como objetivo describir el Cambio Organizacional por covid-19 en las Cooperativas de la ciudad de Pilar, en el año 2020. Al respecto, se estudiaron variables relacionadas con debilidades en las estrategias organizacionales y actitudes frente al proceso de cambio organizacional. Se realizó un diagnóstico que permitió proponer un modelo de cambio en la gestión. El estudio adopta una metodología descriptiva-propositiva, trasversal, con enfoque cualitativo, en una población de cinco cooperativas con sus respectivos gerentes, y sesenta funcionarios distribuidos en cada entidad. Como instrumento de recolección de datos se utilizó el cuestionario “Escala de Aptitudes y Resistencia al Cambio” y una entrevista dirigida a los gerentes, que consta de preguntas formuladas con base en las teorías clásicas de Cambio Organizacional de Lewis y Resistencia al Cambio de Chiavenato. Se ha encontrado que las estrategias implementadas son débiles y afectan la manera de trabajar, traduciéndose en una actitud negativa y resistencia frente al proceso de trasformación. Se plantea un modelo de gestión de cambio para mejorar la adaptabilidad de la organización al contexto covid-19.

Lewis Y antigen expression and postoperative survival in non–small cell lung cancer

1998 ◽  
Vol 66 (5) ◽  
pp. 1745-1750 ◽  
Author(s):  
Fumihiro Tanaka ◽  
Ryo Miyahara ◽  
Yohsuke Ohtake ◽  
Kazuhiro Yanagihara ◽  
Tatsuo Fukuse ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Antigen Expression ◽  
Small Cell ◽  
Postoperative Survival ◽  
Small Cell Lung ◽  
Lewis Y Antigen ◽  
Lewis Y

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission

2021 ◽  
pp. ijgc-2020-002239
Author(s):  
Oren Smaletz ◽  
Gustavo Ismael ◽  
Maria Del Pilar Estevez-Diz ◽  
Ivana L O Nascimento ◽  
Ana Luiza Gomes de Morais ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Monoclonal Antibody ◽  
Epithelial Ovarian Cancer ◽  
Phase Ii ◽  
Progression Free Survival ◽  
Complete Response ◽  
Free Survival ◽  
Platinum Sensitive ◽  
Platinum Based Chemotherapy ◽  
Lewis Y

ObjectiveTo investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with platinum-sensitive recurrent epithelial ovarian cancer who achieved a second complete response after salvage platinum-doublet chemotherapy.MethodsThis single-arm phase II study accrued patients with recurrent epithelial ovarian cancer with Lewis-Y expression by immunohistochemistry who had achieved a second complete response after five to eight cycles of platinum-based chemotherapy. Patients received intravenous infusions of hu3S193, 30 mg/m2 every 2 weeks starting no more than 8 weeks after the last dose of chemotherapy and continuing for 12 doses, until disease progression, or unacceptable toxicity. The primary endpoint was progression-free survival of the second remission. Secondary objectives were safety and pharmacokinetics.ResultsTwenty-nine patients were enrolled. Most had a papillary/serous histology tumor (94%), stage III disease at diagnosis (75%), and five (17%) underwent secondary cytoreduction before salvage chemotherapy. Two patients were not eligible for efficacy but were considered for toxicity analysis. Eighteen patients (62%) completed the full consolidation treatment while nine patients progressed on treatment. At the time of analysis, 23 patients (85%) of the eligible population had progressed and seven of these patients (26%) had died. Median progression-free survival of the second remission was 12.1 months (95% CI: 10.6–13.9), with a 1-year progression-free survival of the second remission rate of 50.1%. The trial was terminated early since it was unlikely that the primary objective would be achieved. The most commonly reported treatment-related adverse events were nausea (55%) and vomiting (51%).ConclusionsHu3S193 did not show sufficient clinical activity as consolidation therapy in patients with recurrent epithelial ovarian cancer who achieved a second complete response after platinum-based chemotherapy.Trial registrationNCT01137071.

scholarly journals Expression of the Carbohydrate Lewis Antigen, Sialyl Lewis A, Sialyl Lewis X, Lewis X, and Lewis Y in the Placental Villi of Patients With Unexplained Miscarriages

2021 ◽  
Vol 12 ◽  
Author(s):  
Zhi Ma ◽  
Huixia Yang ◽  
Lin Peng ◽  
Christina Kuhn ◽  
Anca Chelariu-Raicu ◽  
...  
Keyword(s):  
Expression Pattern ◽  
Recurrent Miscarriage ◽  
Sialyl Lewis X ◽  
Lewis Antigens ◽  
Control Group ◽  
Lewis X ◽  
Sialyl Lewis ◽  
Placental Villi ◽  
Sialyl Lewis A ◽  
Lewis Y

BackgroundLewis antigens such as Sialyl Lewis A (sLeA), Sialyl Lewis X (sLeX), Lewis X (LeX), and Lewis Y (LeY) are a class of carbohydrate molecules that are known to mediate adhesion between tumor cells and endothelium by interacting with its selectin ligands. However, their potential role in miscarriage remains enigmatic. This study aims to analyze the expression pattern of sLeA, sLeX, LeX, and LeY in the placental villi tissue of patients with a medical history of unexplained miscarriages.MethodsParaffin-embedded slides originating from placental tissue were collected from patients experiencing a miscarriage early in their pregnancy (6–13 weeks). Tissues collected from spontaneous (n = 20) and recurrent (n = 15) miscarriages were analyzed using immunohistochemical and immunofluorescent staining. Specimens obtained from legally terminated normal pregnancies were considered as control group (n = 18). Assessment of villous vessel density was performed in another cohort (n = 10 each group) of gestation ages-paired placenta tissue. Protein expression was evaluated with Immunoreactive Score (IRS). Statistical analysis was performed by using Graphpad Prism 8.ResultsExpression of sLeA, sLeX, LeX, and LeY in the syncytiotrophoblast was significantly upregulated in the control group compared with spontaneous and recurrent miscarriage groups. However, no prominent differences between spontaneous and recurrent miscarriage groups were identified. Potential key modulators ST3GAL6 and NEU1 were found to be significantly downregulated in the recurrent miscarriage group and upregulated in the spontaneous group, respectively. Interestingly, LeX and LeY expression was also detected in the endothelial cells of villous vessels in the control group but no significant expression in miscarriage groups. Furthermore, assessment of villous vessel density using CD31 found significantly diminished vessels in all size groups of villi (small villi <200 µm, P = 0.0371; middle villi between 200 and 400 µm, P = 0.0010 and large villi >400 µm, P = 0.0003). Immunofluorescent double staining also indicated the co-localization of LeX/Y and CD31.ConclusionsThe expression of four mentioned carbohydrate Lewis antigens and their potential modulators, ST3GAL6 and NEU1, in the placenta of patients with miscarriages was significantly different from the normal pregnancy. For the first time, their expression pattern in the placenta was illustrated, which might shed light on a novel understanding of Lewis antigens’ role in the pathogenesis of miscarriages.

Sign in / Sign up

Export Citation Format

Share Document